These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18831695)

  • 21. A population pharmacokinetic-pharmacogenetic analysis of atazanavir.
    Kile DA; MaWhinney S; Aquilante CL; Rower JE; Castillo-Mancilla JR; Anderson PL
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1227-34. PubMed ID: 22394315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.
    Fukushima K; Terasaka S; Haraya K; Kodera S; Seki Y; Wada A; Ito Y; Shibata N; Sugioka N; Takada K
    Biol Pharm Bull; 2007 Apr; 30(4):733-8. PubMed ID: 17409512
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
    Calcagno A; Bonora S; Tettoni MC; D'Avolio A; Perri GD; Lanzafame M; Penco G
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):431-2. PubMed ID: 19858926
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
    von Hentig N; Kaykhin P; Stephan C; Babacan E; Stürmer M; Staszewski S; Lötsch J
    Antimicrob Agents Chemother; 2008 Jun; 52(6):2273-5. PubMed ID: 18411323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Atazanavir--booster of the future?
    TreatmentUpdate; 2003; 15(3):5-6. PubMed ID: 17219613
    [No Abstract]   [Full Text] [Related]  

  • 27. Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
    DiCenzo R; Peterson DR; Cruttenden K; Mariuz P; Rezk NL; Hochreiter J; Gelbard H; Schifitto G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3035-9. PubMed ID: 18573930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Conti F; Clementi E
    Ther Drug Monit; 2010 Dec; 32(6):782-6. PubMed ID: 20926993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atazanavir: in pediatric patients with HIV-1 infection.
    Deeks ED
    Paediatr Drugs; 2012 Apr; 14(2):131-41. PubMed ID: 22292486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
    Sparidans RW; Dost F; Crommentuyn KM; Huitema AD; Schellens JH; Beijnen JH
    Biomed Chromatogr; 2006 Jan; 20(1):72-6. PubMed ID: 15954163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Related factors to atazanavir plasma levels in a cohort of HIV positive individuals with undetectable viral load.
    Luz AJ; Poeta J; Linden R; Antunes MV; Caminha LI; Sprinz E
    Braz J Infect Dis; 2013; 17(6):657-60. PubMed ID: 23933406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
    von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
    J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
    Karlström O; Josephson F; Sönnerborg A
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):417-22. PubMed ID: 17159658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
    Dailly E; Tribut O; Tattevin P; Arvieux C; Perré P; Raffi F; Jolliet P
    Eur J Clin Pharmacol; 2006 Jul; 62(7):523-6. PubMed ID: 16763827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacology, pharmacokinetic features and interactions of atazanavir].
    López-Cortés LF
    Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():2-8. PubMed ID: 20116610
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
    Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
    AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
    Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
    Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
    Cattaneo D; Ripamonti D; Baldelli S; Cozzi V; Fucile S; Clementi E
    Fundam Clin Pharmacol; 2013 Apr; 27(2):216-22. PubMed ID: 22044510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.